Dizal Submits NDA to FDA for Sunvozertinib in EGFR Exon20ins NSCLC
Dizal has submitted an NDA to the FDA for sunvozertinib to treat NSCLC patients with EGFR exon 20 insertion mutations after platinum-based chemotherapy.
© Copyright 2025. All Rights Reserved by MedPath